Blockade of programmed death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) has allowed increased local tumor control and survival in patients with lung cancer4 but treatment success may be hindered if total and CD4 lymphocyte counts are reduced.5 Here, CD274 is linked to neoplasm.